# Treating Bacterial Overgrowth in Parkinson's Disease

> **NCT02470780** · PHASE2,PHASE3 · COMPLETED · sponsor: **University of Cincinnati** · enrollment: 4 (actual)

## Conditions studied

- Parkinson's Disease
- Small Intestinal Bacterial Overgrowth

## Interventions

- **DRUG:** Rifaximin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02470780
- **Lead sponsor:** University of Cincinnati
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12
- **Primary completion:** 2017-08
- **Final completion:** 2017-08
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2024-03-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02470780

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02470780, "Treating Bacterial Overgrowth in Parkinson's Disease". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02470780. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*